Merloni F, Ranallo N, Scortichini L, Giampieri R, Berardi R
Cancer Drug Resist. 2022; 2(3):787-802.
PMID: 35582578
PMC: 8992529.
DOI: 10.20517/cdr.2018.006.
de With M, Knikman J, de Man F, Lunenburg C, Henricks L, van Kuilenburg A
Clin Pharmacol Ther. 2022; 112(1):62-68.
PMID: 35397172
PMC: 9322339.
DOI: 10.1002/cpt.2608.
Kim W, Cho Y, Kim D, Lee K
J Pers Med. 2022; 12(2).
PMID: 35207713
PMC: 8875904.
DOI: 10.3390/jpm12020225.
Burns K, Chavani O, Jeong S, Duley J, Porter D, Findlay M
Cancer Chemother Pharmacol. 2021; 87(5):711-716.
PMID: 33687515
DOI: 10.1007/s00280-021-04240-2.
Detailleur S, Segelov E, Del Re M, Prenen H
Ann Gastroenterol. 2021; 34(1):68-72.
PMID: 33414624
PMC: 7774667.
DOI: 10.20524/aog.2020.0551.
The Road so Far in Colorectal Cancer Pharmacogenomics: Are We Closer to Individualised Treatment?.
Simoes A, Fernandez-Rozadilla C, Maronas O, Carracedo A
J Pers Med. 2020; 10(4).
PMID: 33228198
PMC: 7711884.
DOI: 10.3390/jpm10040237.
DPYD and UGT1A1 Pharmacogenetic Testing in Patients with Gastrointestinal Malignancies: An Overview of the Evidence and Considerations for Clinical Implementation.
Varughese L, Lau-Min K, Cambareri C, Damjanov N, Massa R, Reddy N
Pharmacotherapy. 2020; 40(11):1108-1129.
PMID: 32985005
PMC: 8796462.
DOI: 10.1002/phar.2463.
Comparison of 4 Screening Methods for Detecting Fluoropyrimidine Toxicity Risk: Identification of the Most Effective, Cost-Efficient Method to Save Lives.
Capitain O, Seegers V, Metges J, Faroux R, Stampfli C, Ferec M
Dose Response. 2020; 18(3):1559325820951367.
PMID: 32973417
PMC: 7493257.
DOI: 10.1177/1559325820951367.
A Genotyping/Phenotyping Approach with Careful Clinical Monitoring to Manage the Fluoropyrimidines-Based Therapy: Clinical Cases and Systematic Review of the Literature.
Conti V, De Bellis E, Manzo V, Sabbatino F, Iannello F, Dal Piaz F
J Pers Med. 2020; 10(3).
PMID: 32899374
PMC: 7564232.
DOI: 10.3390/jpm10030113.
A Simple and Rapid UPLC-UV Method for Detecting DPD Deficiency in Patients With Cancer.
Marin C, Krache A, Palmaro C, Lucas M, Hilaire V, Ugdonne R
Clin Transl Sci. 2020; 13(4):761-768.
PMID: 32058656
PMC: 7359930.
DOI: 10.1111/cts.12762.
DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice.
Martens F, Huntjens D, Rigter T, Bartels M, Bet P, Cornel M
Front Pharmacol. 2020; 10:1609.
PMID: 32047438
PMC: 6997151.
DOI: 10.3389/fphar.2019.01609.
A case-control study to assess the ability of the thymine challenge test to predict patients with severe to life threatening fluoropyrimidine-induced gastrointestinal toxicity.
Helsby N, Duley J, Burns K, Bonnet C, Jeong S, Brenman E
Br J Clin Pharmacol. 2019; 86(1):155-164.
PMID: 31658382
PMC: 6983507.
DOI: 10.1111/bcp.14153.
Cytomegalovirus enterocolitis in a patient with dihydropyrimidine dehydrogenase deficiency after capecitabine treatment: A case report.
Inoue F, Yano T, Nakahara M, Okuda H, Amano H, Yonehara S
Int J Surg Case Rep. 2019; 56:55-58.
PMID: 30831507
PMC: 6403100.
DOI: 10.1016/j.ijscr.2019.02.022.
Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients.
Stavraka C, Pouptsis A, Okonta L, Desouza K, Charlton P, Kapiris M
Breast Cancer Res Treat. 2019; 175(2):511-517.
PMID: 30746637
PMC: 6533219.
DOI: 10.1007/s10549-019-05144-9.
Evolution of Dihydropyrimidine Dehydrogenase Diagnostic Testing in a Single Center during an 8-Year Period of Time.
Coenen M, Paulussen A, Breuer M, Lindhout M, Tserpelis D, Steyls A
Curr Ther Res Clin Exp. 2018; 90:1-7.
PMID: 30510603
PMC: 6258870.
DOI: 10.1016/j.curtheres.2018.10.001.
Cost Implications of Reactive Versus Prospective Testing for Dihydropyrimidine Dehydrogenase Deficiency in Patients With Colorectal Cancer: A Single-Institution Experience.
Murphy C, Byrne S, Ahmed G, Kenny A, Gallagher J, Harvey H
Dose Response. 2018; 16(4):1559325818803042.
PMID: 30288154
PMC: 6168732.
DOI: 10.1177/1559325818803042.
Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy.
Beumer J, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R
Clin Pharmacol Ther. 2018; 105(3):598-613.
PMID: 29923599
PMC: 6309286.
DOI: 10.1002/cpt.1124.
UPFRONT DPD DEFICIENCY DETECTION TO SECURE 5-FU ADMINISTRATION: PART 2- APPLICATION TO HEAD-AND-NECK CANCER PATIENTS.
Launay M, Ciccolini J, Fournel C, Blanquicett C, Dupuis C, Fakhry N
Clin Cancer Drugs. 2018; 4(2):122-128.
PMID: 29682445
PMC: 5906055.
DOI: 10.2174/2212697x04666170817123425.
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
Ruzzo A, Graziano F, Galli F, Galli F, Rulli E, Lonardi S
Br J Cancer. 2017; 117(9):1269-1277.
PMID: 29065426
PMC: 5709672.
DOI: 10.1038/bjc.2017.289.
New advances in DPYD genotype and risk of severe toxicity under capecitabine.
Etienne-Grimaldi M, Boyer J, Beroud C, Mbatchi L, van Kuilenburg A, Bobin-Dubigeon C
PLoS One. 2017; 12(5):e0175998.
PMID: 28481884
PMC: 5421769.
DOI: 10.1371/journal.pone.0175998.
